Answers are grounded in this paper and cite their sources.
The Orphan Drug Act of 1983 provides incentives to encourage the development of drugs for rare diseases, but available orphan drugs tend to be expensive and targeted to the more common of the rare diseases.
No takes yet. Share an insight, caveat, or question.
Taeho Greg Rhee (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: